Get started
Author

Cunjing Yu

Prostaglandin E 2 constrains systemic inflammation through an innate lymphoid cell–IL-22 axis
2016 · Rodger Duffin, Richard A. O’Connor, et al. · Science · 182
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial
2022 · Caicun Zhou, Dingzhi Huang, et al. · Journal of Thoracic Oncology · 115
PDF
Targeted protein degrader development for cancer: advances, challenges, and opportunities
2023 · Yuan Fang, Shuhang Wang, et al. · Trends in Pharmacological Sciences · 110
PDF
Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis
2017 · Calum T. Robb, Henry J. McSorley, et al. · Journal of Allergy and Clinical Immunology · 68
Filaggrin-null mutations are associated with increased maturation markers on Langerhans cells
2016 · Claire S. Leitch, Eenass Natafji, et al. · Journal of Allergy and Clinical Immunology · 43
PDF
Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial
2008 · C. Yang, J. Shih, et al. · Journal of Clinical Oncology · 32
Nitric oxide induces human CLA+CD25+Foxp3+ regulatory T cells with skin-homing potential
2017 · Cunjing Yu, Amanda Fitzpatrick, et al. · Journal of Allergy and Clinical Immunology · 23
A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors.
2024 · Sanjeev Deva, Caicun Zhou, et al. · Journal of Clinical Oncology · 17
PDF
Abstract CT039: Results from RATIONALE 303: A global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC
2021 · Caicun Zhou, Dingzhi Huang, et al. · Cancer Research · 13
9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)
2011 · T. Mok, V. Gorbunova, et al. · European Journal of Cancer · 8
77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
2020 · Ming-Mo Hou, Kun-Ming Rau, et al. · Journal for ImmunoTherapy of Cancer · 4
Modular Artificial Antigen-presenting Cell Platform for Scalable Expansion and Optimization of Therapeutic Immune Cells
2025 · F. Zhorabek, C. Lau, et al. · Cytotherapy
Abstract 1873: Deep plasma proteome profiling to discover drug treatment related novel biomarkers in non-small cell lung cancer
2025 · Cui Liu, Ruiqi Huang, et al. · Cancer Research
Efficacy, safety, and health-related quality of life from a global phase 3 study of tislelizumab as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): RATIONALE 303
2022 · Caicun Zhou, Dingzhi Huang, et al. · Lung Cancer
P19.01 RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
2021 · Y. Fan, D. Huang, et al. · Journal of Thoracic Oncology
Modulation of immune responses by UV irradiation
2016 · Cunjing Yu · ERA
PDF
Cis-urocanic acid reduces the expression of monocyte-derived dendritic cell costimulatory molecules in a dose-dependent manner
2014 · Claire S. Leitch, Cunjing Yu, et al. · British Journal of Dermatology
Works count: 17
Citation count: 615
H-index: 9
I10-index: 9
Year
Topic
Type